# Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease

> **NCT06409130** · PHASE2 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 270 (actual)

## Conditions studied

- Alcohol-related Liver Disease

## Interventions

- **DRUG:** NNC0194-0499
- **DRUG:** Semaglutide
- **DRUG:** NNC0194-0499 placebo
- **DRUG:** Semaglutide placebo (Group A)
- **DRUG:** Cagrilintide + semaglutide
- **DRUG:** Cagrilintide
- **DRUG:** Cagrilintide placebo
- **DRUG:** Semaglutide placebo (Group B)

## Key facts

- **NCT ID:** NCT06409130
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-05-20
- **Primary completion:** 2025-11-21
- **Final completion:** 2026-01-12
- **Target enrollment:** 270 (ACTUAL)
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06409130

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06409130, "Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06409130. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*